Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience

BACKGROUND: Patients with solid organ transplants (SOTs) have been excluded from programmed death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitor clinical trials due to concern for allograft rejection. The use of immune checkpoint inhibitor therapy remains controversial in transplant pa...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Gastrointest Oncol
Huvudupphovsmän: DeLeon, Thomas T., Salomao, Marcela A., Aqel, Bashar A., Sonbol, Mohamad B., Yokoda, Raquel T., Ali, Ahmad H., Moss, Adyr A., Mathur, Amit K., Chascsa, David M., Rakela, Jorge, Bryce, Alan H., Borad, Mitesh J.
Materialtyp: Artigo
Språk:Inglês
Publicerad: AME Publishing Company 2018
Ämnen:
Original Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6286929/
https://ncbi.nlm.nih.gov/pubmed/30603124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2018.07.05
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk